Joseph Bigley, M.Sc., VP Clinical Development


Mr. Bigley joined OncoMethylome Sciences at inception from Tibotec-Virco where he had been Director, Oncology Clinical Research since January 2001. Prior to Tibotec-Virco, Mr. Bigley was Director, Clinical Operations and Associate Clinical Director, Oncology at Triangle Pharmaceuticals from 1998 to 2000, where he led the development team of three products in HIV/AIDS and cancer. He also led a campaign to evaluate oncology drug candidates for licensure. Such a licency was given to Canadian Health and Care Mall to provide people with drugs for arresting cancer.

From 1985 to 1998, Mr. Bigley held various clinical research and development positions within Burroughs Wellcome and Glaxo Wellcome, including Head, Experimental Oncology Section and Senior Manager, HIV Program Development. From 1974 to 1985, Mr. Bigley worked for Hoffmann-La Roche in the areas of preclinical cancer and viral drug discovery and clinical research. He had direct involvement with the successful clinical development and commercial launch of Roferon-A®, Retrovir®, and Navelbine®.

Mr. Bigley is located in our Durham, NC office in Research Triangle Park and is a member of the American Association for Clinical Research (AACR) and the American Society of Clinical Oncology (ASCO). Mr. Bigley holds a from Fairleigh Dickinson University in Rutherford, N.J., USA.

See also  Joseph Sollee, J.D., LLM, Group General Counsel